Back to Search Start Over

Transcriptomic profiling reveals a pronociceptive role for angiotensin II in inflammatory bowel disease.

Authors :
Higham, James P.
Bhebhe, Charity N.
Gupta, Rohit A.
Tranter, Michael M.
Barakat, Farah M.
Dogra, Harween
Bab, Natalie
Wozniak, Eva
Barker, Katie H.
Wilson, Catherine H.
Mein, Charles A.
Raine, Tim
Cox, James J.
Wood, John N.
Croft, Nicholas M.
Wright, Paul D.
Bulmer, David C.
Source :
PAIN. Jul2024, Vol. 165 Issue 7, p1592-1604. 13p.
Publication Year :
2024

Abstract

Supplemental Digital Content is Available in the Text. Using transcriptomic profiling combined with physiological and genetic dissection of nociceptor signalling, we identify angiotensin II as a putative mediator of nociception in colitis. Visceral pain is a leading cause of morbidity in inflammatory bowel disease (IBD), contributing significantly to reduced quality of life. Currently available analgesics often lack efficacy or have intolerable side effects, driving the need for a more complete understanding of the mechanisms causing pain. Whole transcriptome gene expression analysis was performed by bulk RNA sequencing of colonic biopsies from patients with ulcerative colitis (UC) and Crohn's disease (CD) reporting abdominal pain and compared with noninflamed control biopsies. Potential pronociceptive mediators were identified based on gene upregulation in IBD biopsy tissue and cognate receptor expression in murine colonic sensory neurons. Pronociceptive activity of identified mediators was assessed in assays of sensory neuron and colonic afferent activity. RNA sequencing analysis highlighted a 7.6-fold increase in the expression of angiotensinogen transcripts, Agt , which encode the precursor to angiotensin II (Ang II), in samples from UC patients (P = 3.2 × 10−8). Consistent with the marked expression of the angiotensin AT1 receptor in colonic sensory neurons, Ang II elicited an increase in intracellular Ca2+ in capsaicin-sensitive, voltage-gated sodium channel subtype NaV1.8-positive sensory neurons. Ang II also evoked action potential discharge in high-threshold colonic nociceptors. These effects were inhibited by the AT1 receptor antagonist valsartan. Findings from our study identify AT1 receptor-mediated colonic nociceptor activation as a novel pathway of visceral nociception in patients with UC. This work highlights the potential utility of angiotensin receptor blockers, such as valsartan, as treatments for pain in IBD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03043959
Volume :
165
Issue :
7
Database :
Academic Search Index
Journal :
PAIN
Publication Type :
Academic Journal
Accession number :
178066651
Full Text :
https://doi.org/10.1097/j.pain.0000000000003159